RESEARCH &RELATED - OTHER PROJECT INFORMATION - PROJECT SUMMARY/ABSTRACT CB2 cannabinoid receptor agonists show intriguing therapeutic promise in diverse preclinical models. However, the lack of detailed information about the signal transduction mechanisms underlying the observed in vivo efficacies has thwarted translational efforts aimed at developing CB2-based therapeutics. We have recently described striking functional selectivity (whereby different agonists activate distinct networks of signaling pathways) among different CB2 agonists. We hypothesize that the inability to move CB2 agonists forward from preclinical development to novel therapies is in part due to an insufficient appreciation of the functional selectivity of this class of drugs. We contend that understanding of the mechanism of CB2 agonist functional selectivity is a prerequisite for rationally designing CB2 agonists exhibiting functional selectivity for specific classical CB2 agonist signaling pathways. We will test the hypothesis that selective activation of a restricted set of signaling pathways will produce unique therapeutic benefits by evaluating the effects of novel, functionally selective CB2 agonists in four different preclinical models. This project works iteratively with Core B, and Projects 1 &2 to systematically evaluate functional selectivity of the novel CB2 agonists synthesized in Project 1 (in vitro assays) and determine if CB2 agonist functional selectivity can be exploited to develop more efficacious CB2 agonists for the treatment of chronic pain, inflammation, and reward (in vivo assays). We will test our central hypothesis and accomplish these objectives by completing two specific aims: 1. To characterize the in vitro functional selectivity of rationally designed CB2 agonists from distinct chemical classes. The compounds showing the most distinct profiles of functional selectivity will then be advanced to the second specific aim. 2. To identify the optimal functional selectivity profile of CB2 agonists for suppressing neuropathic pain, inflammation, and reward in vivo. The most promising compounds identified in Aim 1 will be evaluated in Aim 2 for efficacy with acute and chronic (as appropriate) treatment. Completion of the first aim will map CB2 agonist chemotypes associated to specific patterns of functional selectivity.
The second aim will identify signaling networks required to suppress neuropathic pain, inflammation, or reward in our preclinical models, which may or may not involve overlapping functional selectivity profiles. (This approach will also identify the signaling pathways that are not necessary (i.e. dispensable) for a particular behavioral outcome, which is important information to obtain and will be a helpful guide for future medicinal chemistry efforts.) Together, the knowledge gained from these aims will allow us and others to develop novel CB2 ligands with focused pharmacological efficacy and possibly reduced side-effects for treating indications where CB2 agonists are likely to prove beneficial.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northeastern University
United States
Zip Code
Hua, Tian; Vemuri, Kiran; Nikas, Spyros P et al. (2017) Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature 547:468-471
Slivicki, Richard A; Xu, Zhili; Kulkarni, Pushkar M et al. (2017) Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence. Biol Psychiatry :
Finlay, David B; Cawston, Erin E; Grimsey, Natasha L et al. (2017) G?s signalling of the CB1 receptor and the influence of receptor number. Br J Pharmacol 174:2545-2562
Ruehle, Sabine; Wager-Miller, James; Straiker, Alex et al. (2017) Discovery and characterization of two novel CB1 receptor splice variants with modified N-termini in mouse. J Neurochem 142:521-533
Dhopeshwarkar, Amey; Murataeva, Natalia; Makriyannis, Alex et al. (2017) Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists. J Pharmacol Exp Ther 360:300-311
Mallipeddi, Srikrishnan; Janero, David R; Zvonok, Nikolai et al. (2017) Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets. Biochem Pharmacol 128:1-11
Li, Ai-Ling; Carey, Lawrence M; Mackie, Ken et al. (2017) Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB1 Mechanism that is Independent of CB2 Receptors in Mice. J Pharmacol Exp Ther 362:296-305
Dhopeshwarkar, Amey; Mackie, Ken (2016) Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway. J Pharmacol Exp Ther 358:342-51
Järbe, Torbjörn U C; LeMay, Brian J; Thakur, Ganesh A et al. (2016) A high efficacy cannabinergic ligand (AM4054) used as a discriminative stimulus: Generalization to other adamantyl analogs and ?(9)-THC in rats. Pharmacol Biochem Behav 148:46-52
Hua, Tian; Vemuri, Kiran; Pu, Mengchen et al. (2016) Crystal Structure of the Human Cannabinoid Receptor CB1. Cell 167:750-762.e14

Showing the most recent 10 out of 192 publications